Melissa Johnson is an Oncology physician affiliated with Tennessee Oncology. OpenAlex indexes 97 publications with 637 citations (h-index 11); ClinicalTrials.gov lists 10 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
250 25th Ave N
Suite 100
Nashville, TN 372031632
Telephone
615-320-5090Registry record last updated 25 Nov 2014.
Clinical trials
- BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
Sponsor: SCRI Development Innovations, LLC
- RBN-2397 in Combination With Pembrolizumab in Patients With SCCL
Sponsor: Ribon Therapeutics, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
51 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202522 payments$25,657openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20257 payments
- Janssen Global Services, LLCProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
75.9%PD-1 inhibitor75.9%Pembrolizumab100%Part B, office-administered≥16 patientsMusculoskeletal
12.6%RANK Ligand Inhibitor12.6%Denosumab100%Part B, office-administered≥16 patientsSensory organs
7.3%Corticosteroid7.3%Dexamethasone sodium phosphate98%Dexamethasone2%Part D + Part B<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Ian Flinn, MD
Tennessee Oncology
Bipin Savani, MD
Tennessee Oncology
Lester Porter, MD
Tennessee Oncology
Annis Marney, MD, MSCI
Tennessee Oncology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”